DANIEL LEUNG to Antiviral Agents
This is a "connection" page, showing publications DANIEL LEUNG has written about Antiviral Agents.
Connection Strength
1.456
-
Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a. Adv Ther. 2020 07; 37(7):3299-3310.
Score: 0.481
-
Hepatitis C in the pediatric population: transmission, natural history, treatment and liver transplantation. World J Gastroenterol. 2014 Aug 28; 20(32):11281-6.
Score: 0.323
-
Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection. J Pediatr Gastroenterol Nutr. 2024 Jun; 78(6):1342-1354.
Score: 0.158
-
Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study. Hepatology. 2021 07; 74(1):19-27.
Score: 0.130
-
Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper. J Pediatr Gastroenterol Nutr. 2020 09; 71(3):407-417.
Score: 0.122
-
Hepatitis B immunity in the pediatric liver transplant population. Curr Opin Pediatr. 2016 10; 28(5):653-8.
Score: 0.093
-
Hepatitis D in Children. J Pediatr Gastroenterol Nutr. 2015 Sep; 61(3):271-81.
Score: 0.087
-
Epidemiology and long-term outcomes of cytomegalovirus DNAemia and disease in pediatric solid organ transplant recipients. Am J Transplant. 2022 01; 22(1):187-198.
Score: 0.033
-
Comparison of Recommendations for Treatment of Chronic Hepatitis C Virus Infection in Children and Adolescents: A Position Paper of the Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2020 05; 70(5):711-717.
Score: 0.030